Elekta Financial Statements From 2010 to 2025
| EKTAF Stock | USD 5.92 0.03 0.50% |
Check Elekta AB financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Elekta AB's main balance sheet or income statement drivers, such as , as well as many indicators such as . Elekta financial statements analysis is a perfect complement when working with Elekta AB Valuation or Volatility modules.
Elekta |
Elekta AB Company Current Valuation Analysis
Elekta AB's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Elekta AB Current Valuation | 2.71 B |
Most of Elekta AB's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elekta AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Elekta AB has a Current Valuation of 2.71 B. This is 81.1% lower than that of the Healthcare sector and 70.31% lower than that of the Medical Instruments & Supplies industry. The current valuation for all United States stocks is 83.67% higher than that of the company.
Elekta AB Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Elekta AB's current stock value. Our valuation model uses many indicators to compare Elekta AB value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Elekta AB competition to find correlations between indicators driving Elekta AB's intrinsic value. More Info.Elekta AB is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers reporting about 0.36 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Elekta AB is roughly 2.80 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Elekta AB's earnings, one of the primary drivers of an investment's value.About Elekta AB Financial Statements
Elekta AB stakeholders use historical fundamental indicators, such as Elekta AB's revenue or net income, to determine how well the company is positioned to perform in the future. Although Elekta AB investors may analyze each financial statement separately, they are all interrelated. For example, changes in Elekta AB's assets and liabilities are reflected in the revenues and expenses on Elekta AB's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Elekta AB. Please read more on our technical analysis and fundamental analysis pages.
Elekta AB , a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden. Elekta B operates under Medical Instruments Supplies classification in the United States and is traded on OTC Exchange. It employs 4700 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Elekta Pink Sheet
Elekta AB financial ratios help investors to determine whether Elekta Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elekta with respect to the benefits of owning Elekta AB security.